ALNY - アルナイラム・ファ―マシュ―ティカルズ （Alnylam Pharmaceuticals Inc.）

Pune India, Feb. 06, 2023 (GLOBE NEWSWIRE) -- The market has been studied for the below mentioned-segmentation and regional analysis for North America, Europe, Asia, South America, and the Middle East and Africa. These are the key regions where the huntington''s disease treatment market is operating and is predicted to expand soon. The manufacturers and suppliers involved in the huntington''s disease treatment market are present across various countries in the above-mentioned regions. Get Sample Copy of This Report @ https://greyviews.com/reports/huntingtons-disease-treatment-market/536/request-sample The report provides a detailed understanding of the market segments which have been formed by combining different prospects such as the drug type, treatment, and region. Apart from this, the key driving factors, restraints, potential growth opportunities, and market challenges are also discussed in the below paragraphs. The significant players operating in the global huntington''s disease treatment market are Teva Pharmaceutical Industries, Vertex Pharmaceuticals Incorporated, AmpliPhi Biosciences Corp, Valeant Pharmaceuticals International Inc., Pfizer, Lundbeck, Alnylam Pharmaceuticals, Inc., Prana Biotechnology Ltd., Cortex Pharmaceuticals Inc., GlaxoSmithKline among other.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2022 on Thursday, February 23, 2023, before the U.S. financial markets open. Management will provide an update on the Company and discuss fourth quarter and year-end 2022 results as well as expectations for the future via conference call on Thursday, February 23, 2023 at 8

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) closed Thursday at $231.59 per share, up from $229.02 a day earlier. While Alnylam Pharmaceuticals Inc. has overperformed by 1.12%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ALNY rose by 76.87%, with highs and lows ranging from $242.97 to $117.58, whereas […]

ClearBridge is a leading global asset manager committed to active management.

Novartis AG found using ticker (NVS) have now 4 analysts in total covering the stock. The consensus rating is ''Buy''. The range between the high target price and low target price is between 107 and 102 with the average target price sitting at 104.25. Given that the stocks previous close was at 92.16 this indicates there is a potential upside of 13.1%. The day 50 moving average is 89.11 and the 200 moving average now moves to 85.3. The company has a market cap of $198,431m. You can visit the company''s website by visiting: https://www.novartis.com [stock_market_widget type="chart" template="basic" color="green" assets="NVS" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $224,462m based on the market concensus. Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced its first-place ranking in Boston Globe’s 2022 Top Places to Work in the “Largest Employer” category. This marks the second year in a row Alnylam’s takes the top spot in the Largest Employer category (> 1,000 employees). “I’m immensely proud of our team as we reach our eighth consecutive year on Boston Globe’s Top Places to Work,” said Yvonne Greenstreet, MBChB, C

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) concluded the trading at $212.72 on Friday, November 25, with a rise of 2.03% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $208.49 and 5Y monthly beta was reading 0.55 with its price kept floating in the … Alnylam Pharmaceuticals Inc. (ALNY) Rises From The Low: Could It Be A Catbird Seat? Read More »

Related Stocks: ALNY , GOOGL , META , MTCH , MSFT ,

This latest quarterly earnings season for pharma has been a time for companies to vent about President Biden''s new drug price negotiation law, with some companies like Alnylam pointing to orphan drug designation restrictions, and others like Eli Lilly noting the disparities between small and large molecule drugs when it

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Jefferies London Healthcare Conference on Wednesday, November 16, 2022 at 2:05 pm GMT (9:05 am ET) at the Waldorf Hilton in London Stifel 2022 Healthcare Conference on Wednesday, November 16, 2022 at 1:15 pm ET at the Lotte New York Palace Hotel in New York City Evercore ISI 5th Annual

Pfizer (NYSE: PFE ) announced positive top-line results from the pivotal Phase 3 trial assessing the safety, tolerability, and immunogenicity of its investigational pentavalent meningococcal vaccine (MenABCWY) in healthy individuals 10 through 25 years of age. The trial met all primary and secondary endpoints. Pfizer shares traded in a range of $45.7 to $46.29 on day volume of 15.14 million shares, closed regular trading session at $45.94. Alnylam (NASDAQ: ALNY) and Regeneron (NASDAQ: REGN) announced preliminary Phase 1 data supporting the clinical advancement of ALN-HSD, an investigational RNAi therapeutic targeting HSD17B13 in development for the treatment of nonalcoholic steatohepatitis (NASH). Alnylam shares traded in a range of $202.6 to $210.86 on day volume of 771.5 thousand shares, closed regular trading session at $208.48. The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Kymera Therapeutics ’ (NASDAQ: KYMR ) product candidate KT-333 for the treatment of Cutaneous T-cell Lymphoma (CTCL).

A share of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) closed at $208.28 per share on Wednesday, up from $206.59 day before. While Alnylam Pharmaceuticals Inc. has overperformed by 0.82%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ALNY rose by 10.80%, with highs and lows ranging from $236.80 […]

Alnylam (ALNY) and Regeneron (REGN) announced Thursday that early Phase 1 data for ALN-HSD, an experimental therapy for liver disease nonalcoholic steatohepatitis ((NASH)), supported…

CAMBRIDGE, Mass. & TARRYTOWN, N.Y.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Regeneron Pharmaceuticals (Nasdaq: REGN) announced today preliminary Phase 1 data supporting the clinical advancement of ALN-HSD, an investigational RNAi therapeutic targeting HSD17B13 in development for the treatment of nonalcoholic steatohepatitis (NASH). After single-dose evaluation in healthy adult volunteers (Part A), multiple doses of ALN-HSD are being studied in adult patients with NASH

Alnylam (ALNY) has priced its previously announced private offering of $900M principal amount of 1.00% convertible senior notes due 2027.The initial purchasers are granted an option…